Nutanix, Inc. · Technology
Paid for today, but breaks on a small cut — or only looks over-priced at a 9% discount rate.
At 15.0% margin the price requires 10.3% 3y revenue CAGR vs consensus 14.4%, a cushion of -1.3pt (+3.6pt at 1pt lower r) against a 2pt correction cut. It holds only if nothing is cut: a flush-sized slip eats the cushion. Co-mention with NVDA, but not a real channel; the story is VMware share gain.
Would recover if: Consensus growth slips by more than 0.0pt or margin falls below 15%.. We re-check this against analyst estimates every evening.
10 years, at a 15% margin (analysts' margin, cut for cash conversion)
+9.6%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
17 published targets, set before the drop
Linked to AMD, AMZN, GOOGL, MSFT, NVDA
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 87% of reported profit arrived as operating cash, so the test cuts the analysts' 23% margin to 20%. That leaves a cushion of +5pt instead of +8pt, and the smaller of the two decides the group. Two or more red flags: this name cannot come out on top, however large its cushion.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 4, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 47th percentile of 17 published models, almost exactly at the median, meaning it broadly agrees with the middle of the street and requires revenue growth to decelerate from the recent 12.4% down to a 7.4% annual pace.
Whether Nutanix can sustain growth above the 7.4% annual rate the price already assumes, particularly through new initiatives like the ChronoScale agreement; unit volume data can confirm the trajectory, but the specific revenue impact of new partnerships cannot be measured with the tools available.
What the price refuses to pay for, and the full reconstruction, on the NTNX quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names